Today: 30 June 2026
Rigetti stock today: RGTI steadies as Fed minutes and year-end flows keep quantum names jumpy

Rigetti stock today: RGTI steadies as Fed minutes and year-end flows keep quantum names jumpy

NEW YORK, December 30, 2025, 14:34 ET — Regular session

  • Rigetti Computing shares were up about 0.3% in afternoon trading after a choppy session range.
  • Quantum peers IonQ and D-Wave Quantum traded higher, while the broader market held near flat.

Rigetti Computing shares edged up 0.3% to $22.34 on Tuesday afternoon, after swinging about 3% between the day’s high and low. IonQ rose 1.2% and D-Wave Quantum gained 1.6%.

The muted move matters because quantum-computing stocks have become a high-beta pocket of the market, prone to sudden swings when liquidity thins and rate expectations shift. With the calendar turning, traders are re-pricing how much room the Federal Reserve has to ease in 2026.

U.S. stocks were subdued in holiday-thin trading, with investors rotating within technology after a late-year run-up, Reuters reported. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters

The Fed’s December meeting minutes released Tuesday underscored how split policymakers were over cutting rates, as they weighed cooling job growth against stubborn inflation. The central bank lowered its benchmark overnight rate to a 3.5% to 3.75% range in December, and investors now have more detail on the arguments for pausing or cutting again.

That backdrop is closely tied to Rigetti and other early-stage technology shares, which tend to draw in traders when borrowing costs are falling and risk appetite is strong. When investors start to expect fewer or later cuts, the same stocks can give back gains quickly.

Rigetti is a full-stack quantum computing company that runs quantum computers over the cloud and also sells quantum processing units and related services, according to its Reuters profile. Quantum computers use quantum bits, or qubits, which can behave differently from classical bits and may help on certain complex calculations.

The sector has been volatile into the final days of the year, with profit-taking and holiday-depressed institutional volume amplifying day-to-day moves, Investor’s Business Daily reported.

For Rigetti, that means macro headlines can overwhelm company specifics on quiet news days. Traders often lump the stock into a “pure-play quantum” basket, so sympathy moves in IonQ and D-Wave can drive intraday momentum.

Investors are also looking ahead to early-January U.S. data that could reset rate expectations, including December jobs and inflation reports, and the Fed’s next policy meeting later in January.

On the company calendar, the next earnings report is expected in early March, though Rigetti has not confirmed a date. Zacks’ earnings calendar lists March 4, 2026 as the expected release.

When results do arrive, traders will be watching for any update on customer adoption, the pace of contract revenue, and cash burn — the practical markers that can cut through the long-dated promise of quantum computing.

For now, Rigetti’s modest gain on Tuesday highlights a familiar pattern: the stock can move sharply within the day even when it finishes little changed, as year-end positioning and rate-path debates steer speculative tech.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Abivax Jumps 36% After Cancer Safety Fear Eases for Obefazimod
    June 30, 2026, 8:33 AM EDT. Abivax shares climbed 35.77% to 113.10 euros in Paris after new data on its ulcerative colitis drug obefazimod eased cancer safety worries. The updated look, now covering 1,704 patient-years, showed cancer rates tracking with what's expected for the disease, and helped shore up obefazimod's safety profile. Shares had been under pressure after the 50 mg group in Phase 3 turned up higher malignancy numbers. Safety focus stayed high but efficacy held up, with remission topping 50% across doses and relapses. Abivax targets a U.S. FDA filing in the fourth quarter of 2026. In U.S. extended trading, shares picked up 26.4%, narrowing their year-to-date decline to 6.06%.
Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386
Previous Story

Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next
Next Story

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next

Go toTop